AstraZeneca Sues Taro to Block Copy of Brilinta Drug (1)

AstraZeneca Inc. filed two identical lawsuits in separate federal district courts claiming that Taro Pharmaceuticals Inc.’s proposal to manufacture and sell generic blood thinner tablets infringes a patent for the company’s Brilinta branded tablets.

The new suits are the latest attempt by AstraZeneca to block the copying of its blood thinner tablets. The company has two pending federal suits against Torrent Pharmaceuticals and Alembic Pharmaceuticals for their alleged infringement of the same patent.

The most recent complaints, filed in the District of New Jersey and the Southern District of New York, allege that Taro’s generic version of Brilinta makes use ...